ClinicalTrials.gg
RecruitingNCT07197580LUTEONUpdated Apr 1, 2026

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC

A Phase 3 interventional study of 177Lu-TLX250 in ccRCC, Renal Cell Carcinoma (Kidney Cancer) and Renal Cell Carcinoma (RCC), sponsored by Telix Pharmaceuticals (Innovations) Pty Limited. Recruiting at 5 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Telix Pharmaceuticals (Innovations) Pty Limited (part of Telix Pharmaceuticals Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 126 studies in Carcinoma, Renal Cell with a site in Australia — 23 open to participants now, 46 under way, 11 of them phase 3. Carcinoma, Renal Cell · Australia.

Planned enrollment
101st of 119
40 · median 223
Started
2026
with 6 others
Phase 3
37 of 126
3 open now
Primary completion
2027-08
later than 27 of 45 live
Registered
118th of 126
by date

Among the 126 studies in Carcinoma, Renal Cell with a site in Australia, this one is the 101st largest by planned enrollment of the 119 interventional ones that give a count, is one of 7 that started in 2026, is one of 37 in phase 3, reaches primary completion later than 27 of the 45 other live ones, and was the 118th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

23 of the 126 studies in Carcinoma, Renal Cell with a site in Australia are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Carcinoma, Renal Cell with a site in Australia, or all of them as a file.
02

Study summary

Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX250 with investigator's choice of monotherapy aligned with Australian standard-of-care.

Read the detailed description

This is a randomized, open-label, multi-center 3 study evaluating the safety and efficacy of 177Lu-TLX250, a CAIX-targeting radioligand therapy, in adult participants with advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC).

The study consists of two parts:

  • Part 1 (Phase 2a - Dose Optimization): Participants will be randomized to receive one of two dosing regimens of 177Lu-TLX250.

The objective of Part 1 is to determine the recommended Phase 3 dose (RP3D) for use in Part 2.

03

Conditions studied

  • ccRCC
  • Renal Cell Carcinoma (Kidney Cancer)
  • Renal Cell Carcinoma (RCC)
  • Renal Cell Cancer Metastatic
  • Renal Cell Cancer, Recurrent
  • Clear Cell Renal Cell Cancer (ccRCC)

Keywords

  • Carbonic anhydrase 9
  • Clear Cell Renal Cell Cancer
  • Kidney Cancer
  • ccRCC
  • CA9
  • CA-9
  • CAIX
  • Girentuximab
  • CA9 target therapy
  • Positron-Emission Tomography
  • Radiation Therapy
  • Radiopharmaceuticals
  • Targeted Radiation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be aged ≥ 18 years.
  • have provided written , dated and signed by the participant prior to any study-specific procedure;
  • have or recurrent, locally advanced, or RCC with or cytologically confirmed diagnosis of RCC with clear cell component per American Joint Committee on Cancer Staging Manual (Edge SB et al., 2017), with or without sarcomatoid features;
  • have received at least 2 and no more than 3 for locally advanced or metastatic ccRCC including a /PD-L1 inhibitor (at least 2 administrations) and a VEGF/VEGFR-targeting agent (including TKI or mAb) in sequence or in combination;
  • have had radiographic disease progression occurring during or after the most recent line of therapy or intolerance to most recent line of therapy;
  • have at least one according to , version 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions;
  • be CAIX-positive at Screening defined as having at least 1 lesion with a tumor-lesion CAIX ratio of the maximum standardized uptake value (SUVmax) to liver mean standardized uptake value SUVmean) ≥ 1.5 as determined by BICR of 89Zr-TLX250 PET outcomes;
  • have an (ECOG) Performance Status of 0 to 1;
  • have recovered from the AEs related to prior lines of therapy or returned to baseline with the exception of Grade 2 neurotoxicity. Ongoing, controlled AEs, such as hypothyroidism or hypertension, are permitted;
  • have adequate organ function, defined as:
  • Bone Marrow:

    • leukocytes ≥ 3,000/µL;
    • ≥ 1500/µL (administration of granulocyte colony stimulating factor is not allowed within 4 weeks prior to the first administration of 177Lu-TLX250;
    • ≥ 100,000/µL (platelet transfusion is not allowed within 4 weeks prior to the first administration of 177Lu-TLX250); and
    • ≥ 9g/dL (red blood cell transfusion is not allowed within 2 weeks prior to the first administration of 177Lu-TLX250).
  • Liver Function:

    • total ≤ 1.5 × the (ULN). For patients with known Gilbert's Syndrome ≤ 3 × ULN is permitted; and
    • (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN or ≤ 5.0 × ULN for participants with liver metastases.
  • Renal Function:

    • ≥ 40 mL/min as measured by Cockroft-Gault formula or directly calculated by 24h urine;
    • have negative pregnancy test for women of (serum); and

Exclusion criteria

Exclusion Criteria:

  • have any of the following:

    • visceral lesions that are ≥ 1 cm that have a CAIX TLR \< 1;
    • lytic bone metastatic lesions with a soft tissue component of at least 1 cm with a TLR \< 1; and/or
    • at least one metastatic lymph node lesion with short axis ≥ 2.5 cm with a TLR \<1;
  • received prior 177Lu-TLX250 therapy, any other radioligand therapy, or any prior CAIX-targeting therapy;
  • have any known to compounds of similar chemical or biologic composition to girentuximab, DFO or DOTA linker, zirconium or lutetium, and/or any in the study drug or radiographic contrast-agents;
  • has received G-CSF or erythropoietin within 4 weeks prior to laboratory evaluations at Screening;
  • be currently receiving or have received:

    • any radionuclide within 10 half-lives of the radionuclide prior to 89Zr-TLX250 administration;
    • any type of systemic anticancer therapy within 2 weeks before the first administration of 177Lu-TLX250;
    • prior radiotherapy within 2 weeks prior to the first administration of 177Lu-TLX250 (must have recovered from all radiation-related toxicities and not currently require treatment); and/or
    • prior palliative radiation (≤2 weeks of radiotherapy) within 1-week of the first administration of 177Lu-TLX250 for non-central nervous system disease; NOTE: If the investigator feels that the patient is continuing to receive some clinical benefit from standard-of-care (SOC) therapy, the patient may continue SOC therapy up until 2 weeks prior to dosing with 177Lu-TLX250.
  • have known , unless these have been treated and stabilized for at least 4 weeks prior to the first administration of 177Lu-TLX250; Note: Participants with a history of brain metastases must have either a head CT with contrast-or brain MRI performed at Screening to document stable disease prior to the first administration of 177LuTLX250.
  • Have experienced any major trauma including major surgery (such as abdominal/ cardiac/thoracic surgery) within 3 weeks of administration of the first administration of 177LuTLX250;
  • be pregnant or intend to become pregnant, breastfeed, or conceive a child during the study period and for at least 42 days after last administration of 89Zr-TLX250 or 6 months after last administration of 177Lu-TLX250, depending on which study drug is administered last to the respective participant;
  • Note: use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies (see Appendix 10.4).
  • be planning to breastfeed during the study period and for 28 days after last administration of 89ZrTLX250 or 75 days after last administration of 177Lu-TLX250, depending on which study drug is administered last to the respective participant;
  • have active and uncontrolled infections requiring systemic therapy or other severe concurrent disease, which, in the opinion of the investigator, would place the participant at undue risk or interfere with the study;
  • have a history of concurrent with a of ≤ 2 years or requirement of systemic anti-cancer therapy or requirement of local therapy that would confound study results; however; participants with the following malignancies can be enrolled into the study:

    • basal cell or squamous cell carcinoma of the skin;
    • carcinoma in situ of the cervix, breast or bladder; and/or
    • incidental histologic finding of prostate cancer;
  • have a serious, non-healing wound, ulcer, or bone fracture;
  • be unable to stay in the scanner bed with the arms resting out of the thoracic and abdominal fields (i.e., arms alongside the body or raised arm position) for the duration of the scan;
  • have not had resolution of toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for laboratory parameters specified above, Grade 2 alopecia, and/or stable Grade 2 sensory neuropathy, according to National Cancer Institute (NCI-CTCAE) v5.0;
  • have inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis, etc.);
  • have a life expectancy shorter than 3 months;
  • have bleeding or thrombotic disorders or subjects at risk for severe hemorrhage;
  • have experienced any clinically significant bleeding, including hemoptysis or tumor bleeding within 2 weeks prior to the first administration of 177Lu-TLX250;
  • has evidence of a serious active or sub-clinical infection or angina pectoris ( [NYHA] Class III or IV), significantly prolonged or other serious illness(es) involving the cardiac, respiratory, central nervous system, renal, hepatic or hematological organ systems, that might impair the ability to complete this study or could interfere with determination of causality of any adverse effects experienced in this study, or which require treatment that could interact with study treatment; or
  • have any medical or other condition that in the opinion of the investigator(s) would preclude the subject's participation in a clinical study.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    1887MBq 177Lu-girentuximab tetraxetan

    3 infusions of 1887 MBq 177Lu-TLX250 at 8-week intervals or 6 infusions of 1258 MBq 177Lu-TLX250 at 4-week intervals (fractionation of 3 doses of 2516 MBq)

    Radiation: 177Lu-TLX250

  • Experimental
    1258 MBq 177Lu-girentuximab tetraxetan

    6 infusions of 1258 MBq 177Lu-TLX250 at 4-week intervals

    Radiation: 177Lu-TLX250

Interventions

  • Radiation177Lu-TLX250

    3 infusions of 177Lu-TLX250 at 8-week intervals or 6 infusions 177Lu-TLX250 at 4-week intervals

    Also known as: TLX250-Tx, 177Lu girentuximab tetraxetan

06

What researchers measure

Primary outcomes

  1. Dose Optimization -safety and tolerability

    Part 1 of the study is being done to identify the best dose to use for Part 2 of the study. Assessing adverse events of special interest (AESIs), incidence and severity of treatment-emergent adverse events (TEAEs) and frequency, severity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0, seriousness, and relationship of study treatment will be assessed. Laboratory abnormalities will be assessed according to the NCI CTCAE V5.0.

    Time frame: Through study completion, an average of 1.5 years

  2. Efficacy- median mPFS

    Primary objective for Part 2 of the study and secondary objective for Part 1. Monitoring disease progression according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).

    Time frame: Through study completion, an average of 2 years

Secondary outcomes

  1. Monitoring OS (Overall Survival)

    Time from the date of randomization to death from any cause

    Time frame: Through study completion, an average of 2 years

  2. Monitoring ORR (Objective Response Rate)

    Proportion of participants achieving confirmed objective response rate (ORR), i.e., complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) as assessed by a blinded independent central review (BICR)

    Time frame: Through study completion, an average of 2 years

  3. Monitoring DoR (Duration of Response)

    Time from the first documentation of objective response, i.e., complete response (CR) or partial response (PR) to the first documentation of disease progression or death due to any cause as assessed by blinded independent central review (BICR)

    Time frame: Through study completion, an average of 2 years

  4. Monitoring DCR (Disease control Rate)

    The proportion of participants achieving confirmed objective response, i.e., complete response (CR), partial response (PR), or stable disease (SD) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR)

    Time frame: Through study completion, an average of 2 years

  5. Evaluate blood radioactive PK parameter- Cmax (maximum plasma concentration)

    Gamma-counting blood radioactivity will be used to derive this pharmacokinetics parameter

    Time frame: Treatment period (4 months)

  6. Evaluate blood radioactive PK parameter- AUCinf (area under blood concentration time curve from zero to infinity)

    Gamma-counting blood radioactivity will be used to derive this pharmacokinetics parameter.

    Time frame: During Treatment (4 months)

  7. Evaluate blood radioactive PK parameter- t1/2 (Terminal half-life)

    Gamma-counting blood radioactivity will be used to derive this pharmacokinetics parameter.

    Time frame: During Treatment (4 months)

  8. Evaluate blood radioactive PK parameter- CL (Clearance)

    Gamma-counting blood radioactivity will be used to derive this pharmacokinetics parameter.

    Time frame: During Treatment (4 months)

  9. Tumor and Organ-specific 177Lu-TLX250 absorbed radiation values

    Images-radiation values for tumor and lesions will be measured and analyzed after first and second administration of 177Lu-TLX250.

    Time frame: During Treatment (4 months)

  10. TAC for tumor and organ

    Time Activity Curves (TAC) will be used to derive time integrated activity parameters in tumor and organ

    Time frame: During Treatment (4 months)

  11. Tumor- and organ-specific 177Lu-TLX250 residence time

    Residence time of 177Lu-TLX250 in tumor and organs will be derived and interpreted

    Time frame: During Treatment (4 months)

  12. Identification of dose-limiting organ(s)

    Absorbed dose will be compared to maximal dosimetry threshold for each organ to evaluated the dose limiting organ

    Time frame: During Treatment (4 months)

  13. Characterize health utility as measured using the European Quality of Life 5 Dimensions 5 Level Version (EuroQoL EQ-5D-5L)

    Health utility scores from the European Quality of Life 5 Dimensions 5 Level Version (EuroQoL EQ-5D-5L) questionnaire

    Time frame: Through study completion, an average of 2 years

  14. Change from Baseline in EORTC QLQ-C30 Physical Functioning

    Assessed using the EORTC QLQ-C30 questionnaire to evaluate physical functioning.

    Time frame: Through study completion, an average of 2 years

  15. Change from Baseline in EORTC QLQ-C30 Global Health Status/HRQoL

    Assessed using the EORTC QLQ-C30 questionnaire to evaluate overall health-related quality of life.

    Time frame: Through study completion, an average of 2 years

  16. Change from Baseline in FKSI-DRS Subscale

    Assessed using the FKSI-DRS (Functional Assessment of Cancer Therapy - Kidney Symptom Index) to evaluate disease-related symptoms.

    Time frame: Through study completion, an average of 2 years

  17. Incidence and Severity of AESIs and TEAEs

    Adverse events will be assessed and graded per NCI-CTCAE v5.0 criteria.

    Time frame: Through study completion, an average of 2 years

  18. Dosing Delays Due to 177Lu-TLX250-Related TEAEs

    Number of dosing delays attributed to TEAEs related to 177Lu-TLX250.

    Time frame: Through study completion, an average of 2 years

  19. Activity Level Reductions Due to 177Lu-TLX250-Related TEAEs

    Number of participants with reduced activity levels due to TEAEs related to 177Lu-TLX250.

    Time frame: Through study completion, an average of 2 years

  20. Evaluation of Immunogenicity (HACA)

    Incidence of HACA positivity, overall per treatment group, and per visit (to track incidence over time)

    Time frame: Through study completion, an average of 2 years

  21. Evaluation of HACA on PK/Biodistribution

    Evaluate any correlation of incidence of HACA positivity to changes in PK/Biodistribution per treatment group

    Time frame: Through study completion, an average of 2 years

  22. Evaluation of HACA on efficacy/safety

    Evaluate any correlation of incidence of HACA positivity to changes in efficacy/safety end points per treatment group

    Time frame: Through study completion, an average of 2 years

  23. Characterization of HACA neutralizing activity

    For confirmed positive HACA samples, incidence of nAb positivity, overall per treatment group, and per visit (to track incidence over time), as applicable

    Time frame: Through study completion, an average of 2 years

  24. Evaluation of nAb on PK/Biodistribution

    Evaluate any correlation of incidence of nAb positivity to changes in PK/Biodistribution per treatment group

    Time frame: Through study completion, an average of 2 years

  25. Evaluation of nAB on efficacy/safety

    Evaluate any correlation of incidence of nAb positivity to changes in efficacy/safety end points per treatment group

    Time frame: Through study completion, an average of 2 years

  26. Evaluate Radiation Exposure-Response parameter- normalized absorbed dose to individual organs (mGy/MBq)

    Evaluate relationship between normalized absorbed dose to individual organs with DCR, ORR and incidence and severity of AESI

    Time frame: Through study completion, an average of 2 years

  27. Evaluate Radiation Exposure-Response parameter- AUC

    Evaluate relationship between AUC to individual organs with DCR, ORR and incidence and severity of AESI.

    Time frame: Through study completion, an average of 2 years

  28. Evaluate Radiation Exposure-Response parameter- Cmax

    Evaluate relationship between Cmax to individual organs with DCR, ORR and incidence and severity of AESI.

    Time frame: Through study completion, an average of 2 years

  29. Evaluate Radiation Exposure-Response parameter- normalized absorbed dose to tumors (mGy/MBq)

    Evaluate relationship between normalized absorbed dose to tumor with DCR, ORR and incidence and severity of AESI.

    Time frame: Through study completion, an average of 2 years

07

Study locations

1 of 5 sites recruiting
08

References and documents

Publications

  • Muselaers CH, Boers-Sonderen MJ, van Oostenbrugge TJ, Boerman OC, Desar IM, Stillebroer AB, Mulder SF, van Herpen CM, Langenhuijsen JF, Oosterwijk E, Oyen WJ, Mulders PF. Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. Eur Urol. 2016 May;69(5):767-70. doi: 10.1016/j.eururo.2015.11.033. Epub 2015 Dec 23. PubMed 26706103 ↗
  • Stillebroer AB, Boerman OC, Desar IM, Boers-Sonderen MJ, van Herpen CM, Langenhuijsen JF, Smith-Jones PM, Oosterwijk E, Oyen WJ, Mulders PF. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2013 Sep;64(3):478-85. doi: 10.1016/j.eururo.2012.08.024. Epub 2012 Aug 21. PubMed 22980441 ↗

Individual participant data

Plan to share: No — We have opted not to share individual participant data due to concerns regarding participant privacy and the absence of explicit consent for data sharing in the original trial protocol.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.

Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's planned 17 months is below that.

Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2025
First posted
Sep 29, 2025
StartActual
Mar 25, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Feb 28, 2029
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07197580
Collaborators
Medpace, Inc.
Responsible party
Sponsor
First posted
Sep 29, 2025
Start date
Mar 25, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Apr 1, 2026

Study contacts

Prson Gautam, PhD
Contact
prson.gautam@telixpharma.com
19196508158
Lily Nahidi, PhD
Contact
lily.nahidi@telixpharma.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion